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Abstract: Notwithstanding the functional role that the aggregates of some amyloidogenic proteins can 
play in different organisms, protein aggregation plays a pivotal role in the pathogenesis of a large number 
of human diseases. One of such diseases is Alzheimer’s disease (AD), where the overproduction and 
aggregation of the β-amyloid peptide (Aβ) are regarded as early critical factors. Another protein that 
seems to occupy a prominent position within the complex pathological network of AD is the enzyme 
acetylcholinesterase (AChE), with classical and non-classical activities involved at the late (cholinergic 
deficit) and early (Aβ aggregation) phases of the disease. Dual inhibitors of Aβ aggregation and AChE 
are thus emerging as promising multi-target agents with potential to efficiently modify the natural course 
of AD. In the initial phases of the drug discovery process of such compounds, in vitro evaluation of the 
inhibition of Aβ aggregation is rather troublesome, as it is very sensitive to experimental assay 
conditions, and requires expensive synthetic Aβ peptides, which makes cost-prohibitive the screening of 
large compound libraries. Herein, we review recently developed multi-target anti-Alzheimer compounds 
that exhibit both Aβ aggregation and AChE inhibitory activities, and, in some cases also additional 
valuable activities such as BACE-1 inhibition or antioxidant properties. We also discuss the development 
of simplified in vivo methods for the rapid, simple, reliable, unexpensive, and high-throughput amenable 
screening of Aβ aggregation inhibitors that rely on the overexpression of Aβ42 alone or fused with 
reporter proteins in Escherichia coli.  
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INTRODUCTION 
Many distinct proteins and peptides can undergo under certain (patho)physiological conditions 
conformational rearrangements from the native unordered and soluble states into misfolded -sheet rich 
conformers with exposed hydrophobic surfaces, which enable intermolecular attractive forces leading to 
aggregation into increasingly ordered and sized oligomeric and polymeric species, the so-called amyloid 
fibrils, which can eventually deposit within or around cells [1,2]. Notwithstanding the diverse amino acid 
sequences, size and in vivo distribution of amyloidogenic proteins, their aggregation seems to proceed 
through a similar process, namely a nucleation-dependent polymerization, which involves the initial 
formation of small oligomeric ordered nuclei as the rate-limiting step when the concentration of the 
amyloidogenic protein reaches a critical point, followed by the amyloid fibril growth by the 
thermodynamically favorable successive addition of monomers [3,4]. Moreover, the complex multi-step 
aggregation process of the different amyloidogenic proteins seems to result in very similar highly ordered 
structures which share a number of common features such as high insolubility and stability as well as 
similar morphological and tinctorial properties [4,5]. 
Increasing evidence suggests that amyloid fibers or some intermediate aggregated species might display 
specific physiological nontoxic roles [1,2,6]. Thus, several functional amyloids have been described in 
bacteria, including the Escherichia coli curli fibers, which play a role in bacterial growth in biofilms, the 
Streptomices coelicolor chaplins, which are involved in the development of aerial hyphea, or the 
Klebsiella pneumoniae microcin E492 and the harpins produced by plant pathogens, with a role in 
defense mechanisms. Also, functional amyloids have been described in eukaryotic cells, for example 
some yeast prion proteins such as Ure2p, involved in the regulation of the use of poor nitrogen sources, or 
Sup35p, with a role as the translation release factor in Saccharomyces cerevisiae, or the cytoplasmic 
polyadenylation element binding (CPEB) protein of the sea slug Aplysia californica, which has been 
found to act as a prion when expressed in yeast and has been suggested to play a role in the formation of 
long-term memory [6], or F-actin microfilaments, which participate in numerous cellular processes such 
as muscular contraction or cell motility and division, among others [2]. 
However, amyloid aggregation has been mostly associated with the pathogenesis of a number of human 
diseases. Indeed, aggregation of disease-specific amyloidogenic proteins and subsequent deposition 
seems to be the root cause of a broad range of disorders, called amyloidoses, which encompass 
neurodegenerative diseases such as Alzheimer’s, Parkinson’s, and Huntington’s diseases or spongiform 
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encephalopathies or systemic amyloidoses such as type II diabetes, cataracts, lysozime and fibrinogen 
amyloidosis, amyloid light-chain amyloidosis, amyloid A amyloidosis, or amyloid transthyretin 
amyloidosis [1,7]. Again some similarities have been proposed to exit in the mechanisms underlying the 
cellular toxicity of the amyloid aggregates of the different amyloidogenic proteins [3,5]. 
In the particular case of Alzheimer’s disease (AD), two amyloidogenic proteins are involved in the onset 
and progression of the neurodegenerative cascade, namely the -amyloid peptide (A) and the tau 
protein, whose aggregates accumulate extra- and intra-cellularly, respectively, giving rise to the two main 
hallmarks of AD, the senile plaques and the neurofibrillary tangles. Even though the protein tau plays an 
important role in the neurodegenerative process, its processing, hyperphosphorylation and aggregation 
seem to take place downstream of A formation and aggregation, as it seems to be the case of other 
important events such as inflammation and oxidative stress [8-10]. A is a short peptide from 38 to 43 
amino acids that is formed upon cleavage of a transmembrane glycoprotein, the amyloid precursor protein 
(APP), by the sequential action of the enzymes -secretase (or BACE-1) and -secretase. The most 
abundant form of A is 40 residues in length (A40), whereas the form of 42 amino acids (A42) is the 
one that most readily aggregates and the most neurotoxic. The credence that abnormally increased A 
production and subsequent aggregation in brain is the real culprit of the neurodegenerative cascade of AD 
constitutes the core principle of the prevailing hypothesis on the etiology of AD, the amyloid cascade 
hypothesis [10-17]. Thus, the increased brain levels of A resulting from an imbalance between its 
production and its clearance, and its aggregation under the increased concentration conditions trigger a 
cascade of deleterious events that ultimately lead to dysfunction and death of neurons, neurotransmitter 
deficits, and dementia. 
Compelling evidence from genetic studies strongly support the amyloid cascade hypothesis, inasmuch as 
all familial cases of AD are associated with mutations or polymorphisms in genes that result in increased 
production of A or of its amyloidogenicity (either increased levels of A42 or increased ratio 
A42/A40), namely the genes of APP, apolipoprotein E, presenilin 1, and presenilin 2, in chromosomes 
21, 19, 14, and 1, respectively [18]. Similarly, modulation of A production or degradation by the action 
of external factors might be the cause of the much more common sporadic cases of AD [19]. Also, the 
fact that in transgenic mice overexpressing human mutant APP gene many pathological hallmarks of AD 
are recapitulated gives also support to this hypothesis. 
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The most crucial factor determining A toxicity seems to be the aggregation state [20]. Thus, it was 
initially thought that mature A fibrils deposited in senile plaques were the neurotoxic species in AD 
pathogenesis. However, brain A plaque load does not correlate well with clinical progression of AD, and 
many AD patients with severe memory impairment do not show A plaques at post-mortem analysis, 
whereas normal individuals can have A plaques without cognitive deficits [15,21-23]. Increasing 
evidence indicates that soluble A oligomers or prefibrillar aggregation intermediates are indeed the 
major culprit for neurotoxicity [24,25]. Indeed, the levels of A oligomers equate with AD severity, and 
soluble A oligomers have been found to be able to inhibit long term potentiation in the hippocampus, 
and, therefore, to disrupt synaptic plasticity [26]. Notwithstanding the currently widely accepted role of 
A oligomers as the neurotoxic species responsible of triggering the neurodegenerative cascade of AD, 
the final A fibrils seem also not to be devoid of toxicity [10,27]. 
The amyloid cascade hypothesis has provided the rational framework for the development of therapeutic 
interventions, labelled as “disease-modifying” because they are expected to be capable of preventing or 
delaying the onset of AD and slowing or halting its progression, thereby going far beyond the currently 
available anti-Alzheimer drugs that are regarded as merely symptomatic [28]. Hence, the discovery of 
anti-Alzheimer drug candidates aimed at reducing A production through inhibitors of - and -
secretases, at reducing A aggregation, or at increasing A clearance by active or passive 
immunotherapies, has been very actively pursued in the past decades. Even though the predominant 
processing pathway of APP, which involves the initial action of -secretase followed by -secretase, does 
not lead to amyloidogenic peptides, A is continuously secreted under normal physiological conditions 
and might play a functional role, as it has been found for other amylodogenic proteins (see above). 
Indeed, provocative evidences for a physiological role of A in synaptic transmission and neuronal 
viability have been reported [29,30]. Because A might play physiological roles, inhibition of A 
aggregation, without having to entirely remove A from brain, is emerging as a very promising strategy 
in the search for effective and safe medications for AD. In most cases, A aggregation inhibitors are 
discovered through screening campaigns [2,4,5,9,20,24,31-33], but important efforts are being carried out 
to understand the mechanisms involved in A aggregation and in its inhibition by small molecule drug 
candidates and to develop suitable computational approaches that enable the rational design of novel A 
aggregation inhibitors [34-38]. 
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Disappointingly, despite huge research efforts and financial investments different A-directed anti-
Alzheimer drug candidates have failed in advanced clinical trials, including tramiprosate (Alzhemed, 3-
amino-1-propanesulfonic acid, Fig. 1), the most prominent A aggregation inhibitor, which failed to 
demonstrate cognitive benefits in phase III trials.  
 
H2N SO3H
tramiprosate, 1  
 
Fig. (1). Chemical structure of the A aggregation inhibitor anti-Alzheimer drug candidate tramiprosate. 
 
The clinical failures of advanced supposedly disease-modifying A-directed drug candidates might be 
ascribed, however, to a number of factors other than their apparent lack of efficacy, such as confusion of 
clinical outcomes by the occurrence of adverse effects (for example the meningoencephalitis produced by 
the A vaccine AN1792 or the side effects derived from Notch inhibition by -secretase inhibitors), 
pharmacokinetic issues (poor brain penetration in the case of tramiprosate), and especially the timing of 
the therapies [28], as these drug candidates are clinically assayed when AD patients become symptomatic 
and are diagnosed as such, which occurs years or decades after the amyloid pathology started and 
progressed, which leaves no much room for a disease-modifying intervention because at that point 
neurodegeneration is too widespread. With this in mind, and while awaiting the development of suitable 
biomarkers and technologies that allow an early diagnosis of AD and, hence, an advanced therapeutic 
intervention with more chances of success, A aggregation and production remain viable targets to derive 
effective medications. However, there is an increasing perception that these targets should be approached 
in a different way. Human disease, in general, and evidently complex multi-factorial diseases as AD in 
particular, are increasingly believed not to result from an abnormality in a single protein target but to 
consist of a complex pathological network of interconnected protein targets endowed with compensatory 
signaling and redundant pathways that render ineffective the modulation of a single target of the network 
[39]. This conception challenges both the relevance of overly simplistic in vitro assays of drug candidates 
against a particular protein target isolated from its complex physiological environment and the 
effectiveness of single-target therapies, and boosts the use of phenotypic in vivo tests and the 
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development of multi-target therapies, particularly multi-target single-molecule drugs, i.e. the so-called 
multi-target drugs, multiple ligands or multi-target-directed ligands [40,41]. 
In the case of AD, the notions that it is not a straightforward process, that A is one of the causative 
factors, and not the sole factor contributing to AD neuropathogenesis [15], and that AD should be better 
confronted with drugs that simultaneously hit A formation and/or aggregation as well as other targets are 
gaining credence [42-46], and important endeavors are being done for charting the protein-protein 
interactions network of AD [47] to rationally select those targets and pathways to be hit by multi-target 
drugs that may overcome the robustness of the pathological network of AD. 
Among the different targets involved in AD neuropathogenesis that can be hit together with A formation 
and/or aggregation by multi-target drug candidates, the enzyme acetylcholinesterase (AChE) deserves a 
special attention. AChE is the target of four out of the five marketed anti-Alzheimer drugs, namely the 
AChE inhibitors tacrine, donepezil, galantamine, and rivastigmine (Fig. 2), which, together with the 
NMDA receptor antagonist memantine, are used to alleviate the cognitive and functional decline of AD 
patients in mild to moderate or moderate to severe symptomatic stages of the disease.  
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Fig. (2). Chemical structures of marketed anti-Alzheimer drugs. 
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Despite the primary involvement of AChE at the level of the neurotransmitter deficits that appear as a 
downstream event in the neurotoxic cascade of AD, the finding of Inestrosa one decade ago that AChE 
can promote A aggregation upon binding to form an A-AChE complex and increase its neurotoxicity 
as an early event in AD [48-50] shifts AChE as an upstream element in AD neuropathogenesis, thereby 
increasing the interest in the development of multi-target compounds simultaneously directed to A and 
to AChE, especially taking into account that: i) the binding site of A within AChE has been identified, 
and ii) this site, the so-called peripheral anionic site (PAS) of AChE, is placed at the mouth of a narrow 
20 Å-deep gorge at the bottom of which is placed the catalytic anionic site (CAS) of AChE [51], which 
enables the rational design of both peripheral site AChE inhibitors (AChEIs) and dual binding site 
AChEIs, able to simultaneously bind to both PAS and CAS [52-62]. Apart from a high AChE inhibitory 
activity, dual binding site AChEIs should be endowed, by definition, with the ability to inhibit the AChE-
induced A aggregation. Also, a number of dual binding site AChEIs have been screened and found to be 
active against A self-aggregation. Herein, we review recent reports on the development of new multi-
target anti-Alzheimer drug candidates that hit both AChE and A aggregation, induced by AChE and/or 
spontaneous. 
Whereas the in vitro determination of cholinesterase inhibitory activity, usually carried out by the method 
of Ellman [63], is a quite well established and reproducible standard procedure, in vitro determination of 
the A anti-aggregating activity is rather troublesome. Apart from the artificiality and over-simplicity of 
in vitro assays, A aggregation is extremely sensitive to experimental conditions [9,15], thereby 
challenging the reliability of the obtained results regarding their physiological relevance or making it 
difficult the comparison between studies by differents groups. Herein, we also review on novel simplified 
in vivo models of A aggregation that allow an easy, rapid, inexpensive, and more physiological 
screening of A aggregation inhibitors. 
 
DUAL INHIBITORS OF A AGGREGATION AND AChE 
Tacrine-based dimers and hybrids 
Tacrine is the pharmacophoric moiety most consistently found in the chemical structures of heterodimeric 
or hybrid dual inhibitors of AChE and A aggregation developed so far, likely because of the ease of 
synthesis of the intermediates bearing the tacrine scaffold and also because of the outstanding multi-target 
pharmacological profile of its heptamethylene-linked dimer, bis(7)-tacrine or bis(7)-cognitin, the first 
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rationally designed dual binding site AChEI [53,57,64-66]. The development of novel classes of multi-
target anti-Alzheimer tacrine derivatives has been recently reviewed [67,68]. In this section, we 
summarize recent reports on novel tacrine-based dimeric or hybrid compounds that exhibit a multi-target 
profile, encompassing AChE and A aggregation inhibitory activities, among others. 
The research groups of Bolognesi and Minarini have recently reported the synthesis and evaluation of 
novel derivatives of bis(7)-tacrine where the heptamethylene linker was replaced by more rigid aromatic 
spacers or by a unit of the neuroprotective and antioxidant agent cystamine, respectively [69,70]. The 
rationale behind the rigidification of the linker that connects both tacrine units by introduction of oligo(p-
phenylene) groups, as in the biphenyl-linked tacrine dimer 8 (Fig. 3), was triple, as improvements in the 
interactions with human AChE (hAChE), A and BACE-1 were pursued. On the one hand, the presence 
of the aromatic rings in the linker might allow to gain additional -stacking interactions with the aromatic 
residues that line the active site gorge of AChE, thereby enabling a three-site (CAS, PAS, and mid-gorge) 
interaction, and hence a strong interaction, with AChE. On the other hand, the planar aromatic surfaces of 
these aromatic rings of the linker might lead to a better interaction with A, thereby interfering with the 
aggregation process. Also, the high molecular hindrance provided by the linker might allow a better fit 
into the extended substrate binding site of BACE-1. Indeed, tacrine dimer 8 turned out to be more potent 
than the parent compound bis(7)-tacrine as inhibitor of A42 self-aggregation (76% vs 51% inhibition at 
10 μM) and as inhibitor of BACE-1 (90% vs 27% inhibition at 10 μM), but less potent for hAChE 
inhibition (Table 1). Even though the interactions of one tacrine unit at the CAS and of the biphenyl 
linker with mid-gorge aromatic residues of AChE were suggested by molecular docking experiments, a 
lack of interaction with Trp286 (hAChE numbering), the characteristic PAS residue, as a consequence of 
the rigidity imposed by the biphenyl system might account for the 4-fold lower hAChE inhibitory activity 
of 8 relative to bis(7)-tacrine. Despite the missing interaction with the PAS of AChE, protrusion beyond 
the PAS of one tacrine unit to the solvent-exposed gorge entrance seems to account for the significant 
inhibitory activity of 8 against the AChE-induced aggregation of A40. Worthy of note, compound 8 was 
more potent than the parent compound as inhibitor of human butyrylcholinesterase (hBChE; IC50=0.86 vs 
5.66 nM), an enzyme that exert a compensatory effect in response to a great decrease in brain AChE 
activity as AD progresses, thereby constituting a valuable target for anti-Alzheimer agents [71]. 
Replacement of the heptamethylene linker of bis(7)-tacrine by a cystamine unit was carried out with the 
hope that the resulting compound, the cystamine-tacrine dimer 9 (Fig. 3) would retain the antioxidant, 
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radical scavenging, and neuroprotective properties of cystamine as well as the dual inhibition against 
cholinesterases and A aggregation of bis(7)-tacrine [70]. Even though the cystamine-tacrine dimer 9 was 
less potent than bis(7)-tacrine against hAChE and AChE-induced and self-induced A aggregation (Table 
1) and roughly equipotent for hBChE inhibition (IC50 4.23 vs 5.66 nM), 9 was clearly superior to bis(7)-
tacrine in terms of neuroprotective activity and toxicity in human neuroblastoma SH-SY5Y cell cultures. 
Thus, compound 9 was able to protect SH-SY5Y cells against hydrogen peroxide insult even at a dose as 
low as 5 nM, the protective effect being complete at 0.5 μM. Apparently, this protective effect of 9 was 
related to its ability to scavenging oxygen peroxide, thereby reducing reactive oxygen species (ROS) 
production, likely by activation of the prosurvival kinases ERK1/2 andAkt [70]. 
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Fig. (3). Chemical structures of tacrine dimers and tacrine-4-aminoquinoline heterodimers. 
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 Table 1. In Vitro Dual Inhibitory Activities of Tacrine Dimers and Tacrine-4-Aminoquinoline 
Heterodimers Against AChE and A Aggregation 
Compound hAChE  
(IC50 nM) 
AChE-induced 
A40 aggregation 
(% inhibition at 100 μM)a 
self-induced 
A42 aggregation 
(% inhibition at 10 μMb  
and/or IC50 μM) 
Bis(7)-tacrine, 7 0.81 68 51 / IC50 8.4 μM  
8 3.61 62 76 
9 5.04 53 IC50 24 μM 
10 1.05 46  
(±)-11 1.38 67 64 
a [inhibitor (I)]=100 μM, [A40]=230 μM, [AChE]=2.30 μM, A40:AChE ratio 100:1. b [I]=10 μM, 
[I]:[A42] ratio 1:5. 
 
The group of Rampa reported the synthesis of compound 10 (Fig. 3), closely related structurally to bis(7)-
tacrine, bearing a chlorine atom at position 6 of a tacrine unit to increase the affinity toward the CAS of 
AChE and an indenoquinoline moiety to interact with the PAS [72]. Compound 10 was found to be 
equipotent to bis(7)-tacrine as inhibitor of hAChE (Table 1). In agreement with kinetic studies that 
suggeted a mixed-type inhibition of hAChE by 10, i.e. the ability to interact with both CAS and PAS, this 
compound was able to inhibit the AChE-induced aggregation of A40, albeit with lower potency than 
bis(7)-tacrine [72]. Moreover, indenoquinoline-tacrine heterodimer 10 turned out to be a potent inhibitor 
of hBChE (IC50 64 nM) and, very interestingly, it also displayed a potent BACE-1 inhibitory activity (IC50 
1.0 μM), being 7.5-fold more potent than bis(7)-tacrine (IC50 7.5 μM), likely as a consequence of its 
greater molecular size, whereas none of its monomeric constituents, neither tacrine nor the 
indenoquinoline fragment, were active for BACE-1 inhibition. 
The group of Muñoz-Torrero recently developed a family of heterodimeric compounds that are also 
structurally related to bis-tacrines, namely the huprine-tacrine heterodimers [73], in which a unit of 
tacrine was connected through different linkers to a unit of huprine Y, a high affinity inhibitor of the CAS 
of AChE that was designed by merging the structures of the natural AChE inhibitor huperzine A and 
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tacrine [74]. Among these compounds, heterodimer (±)-11 (Fig. 3) exhibited a very interesting multi-
target profile, encompassing a highly potent inhibitory activity toward hAChE, resulting form its dual site 
binding to CAS and PAS as predicted by molecular dynamics simulations and kinetic studies, as well as 
moderately potent inhibitory activities toward AChE-induced and self-induced aggregations of A40 and 
A42, respectively (Table 1). Worthy of note, this compound was found to be able to block the 
aggregation induced by AChE of another amyloidogenic protein, namely the prion peptide PrP106-126, 
one of the key domains involved in the conformational change and aggregation of the prion protein (87% 
inhibition at 100 μM, IC50 69 nM). The facts that AChE can act as a pathological chaperone promoting 
the aggregation of distinct amyloidogenic proteins such A and PrP106-126 [75], and also of PrP82-146 
[76], the main component of the amyloid plaques in patients with Gerstmann-Sträussler-Scheinker 
disease, and that huprine-tacrine heterodimers as (±)-11 can inhibit both processes support the 
increasingly accepted notion that amyloidoses share common mechanisms and might also be confronted 
with common therapeutic interventions [77]. Regarding the multi-target profile of (±)-11, it is also a 
potent inhibitor of hBChE (IC50 74 nM) but it was found to be inactive against BACE-1, contrary to its 
analog bearing a chlorine atom at position 6 of the tacrine unit (IC50 for BACE-1 inhibition 5 μM). 
Finally, ex vivo experiments in OF1 mice confirmed the ability of the huprine-tacrine heterodimer (±)-11 
to cross the blood-brain barrier (BBB) after intraperitoneal administration and inhibit brain AChE. 
Other tacrine-based hybrid compounds with dual action on AChE and A aggregation in which the 
tacrine unit is linked to an heteroaromatic system different from 4-aminoquinoline have been also 
recently developed. The group of Wang and Kong has designed a series of hybrids that consisted of a 
tacrine unit connected to a coumarin system through a linker containing a piperazine ring. Unlike most 
tacrine-based dimeric or hybrid compounds developed so far, where the nitrogen atom at position 9 of the 
tacrine unit is an amino group, in these coumarin-tacrine hybrids, exemplified by compound 12 (Fig. 4), 
the exocyclic nitrogen atom of the tacrine unit was introduced in an amide functionality with a triple 
purpose, namely enabling metal ions chelation, promoting choline uptake, and decreasing toxicity [78]. 
Moreover, the piperazine moiety of the linker, which should be protonated at physiological pH, was 
expected to endow the coumarin-tacrine hybrids with the ability to establish cation- interactions with 
AChE mid-gorge aromatic residues, which would add to the expected interactions of the tacrine and 
coumarin moieties at the CAS and PAS of AChE, respectively. Indeed, kinetic and molecular docking 
studies confirmed the expected three-site binding mode of 12 to AChE. The tight binding of 12 to AChE 
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was also evidenced by its potent inhibition of electric eel AChE (eeAChE, IC50 92 nM), clearly higher 
than that of the parent monomeric tacrine (IC50 269 nM, in the same assay conditions). Also, compound 
12 at 20 μM, was able to inhibit by 68% the aggregation of A42, more potently than the positive 
reference compound curcumin (42% inhibition at 20 μM). Also, as expected, compound 12 was able to 
chelate Cu2+ and Fe2+, which might be important for lowering ROS production, and was found to be 
nontoxic to human neuroblastoma SH-SY5Y cells at concentrations up to 50 μM [78]. 
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Fig. (4). Chemical structures of other tacrine-based hybrids. 
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On the basis of previous results from screening campaigns pursuing the discovery of A anti-aggregating 
compounds, which suggested an important role of the methylenedioxybenzene moiety for A anti-
aggregating activity, and taking into account that this moiety seemed to be also important for the AChE 
inhibitory activity of a series of lignans, isolated from Schizandra chinensis [79], the group of Huang 
designed a series of hybrid compounds, such as 13 (Fig. 4), which contained a tacrine unit linked to a 
methylenedioxybenzene or related multialkoxybenzene moieties. These multialkoxybenzene-tacrine 
hybrids were expected to act as dual binding site AChEIs with both AChE and A aggregation inhibitory 
activities [80]. Both, kinetic and molecular docking studies suggested a dual site binding of 13 to AChE, 
with the tacrine unit occupying the CAS of AChE and the methylenedioxybenzene ring stacked against 
the characteristic Trp279 PAS residue (Torpedo californica AChE (TcAChE) numbering). As expected 
from this binding mode, compound 13 exhibited a potent inhibitory activity of eeAChE (IC50 7.98 nM), it 
being equipotent toward equine BChE (IC50 7.94 nM). Also, 13, at 20 μM and with a ratio [I]:[A42] 1:1, 
inhibited A42 self-aggregation by 65%. Worthy of note, compound 13 was more potent that the 
reference compounds for AChE and A aggregation inhibition, tacrine (IC50 eeAChE 193 nM, in the 
same assay conditions) and curcumin (52% inhibition of A42 aggregation), respectively. 
Starting from the knowledge that synthetic derivatives of oxoisoaporphine displayed a high AChE 
inhibitory activity, arising from an interaction of the 1-azabenzanthrone moiety with the PAS [81], Tang 
et al. designed a series of novel dual binding site AChEIs bearing a tacrine unit for the interaction with 
CAS and an oxoisoaporphine moiety for the interaction with PAS [82]. Among these compounds, 14 
(Fig. 4) emerged as a potent inhibitor of eeAChE (IC50 3.4 nM) and equine BChE (IC50 110 nM), as well 
as a potent inhibitor of both AChE-induced aggregation of A40 (83% inhibition at 100 μM) and self-
induced aggregation of A42 (80% inhibition at 10 μM, with a ratio [I]:[A42] 1:2), it being more potent 
than tacrine for eeAChE inhibition (IC50 104 nM, in the same assay conditions) and curcumin for AChE- 
and self-induced A aggregation inhibition (35% and 42% inhibition, respectively, in the same assay 
conditions), but less potent than Congo red for inhibition of AChE-induced A40 aggregation (97% 
inhibition) [82]. Disappointingly, an uncertain BBB permeation was predicted for the oxoisoaporphine-
tacrine hybrid 14 in the PAMPA-BBB assay, thereby challenging its potential interest for AD treatment. 
Because the phenylthiazole scaffold is present in compounds with inhibitory activity against the 
aggregation of tau protein [83], the group of Chen inferred that it might also afford Aβ anti-aggregating 
activity, and conjugated it with a unit of tacrine through different linkers [84]. The 2-amino-4-
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phenylthiazole-tacrine hybrids 15 and 16 (Fig. 4) emerged as multi-target compounds endowed with 
potent eeAChE inhibitory activity (81 nM and 158 nM, respectively), and moderately potent equine 
BChE inhibitory activity (467 nM and 588 nM, respectively), and, as expected, a significant inhibition of 
Aβ42 self-aggregation (70% and 72% inhibition at 20 μM, with a ratio [I]:[Aβ42] 1:1) [84]. Even though 
these compounds were less potent cholinesterase inhibitors than the parent tacrine (64 nM and 3 nM for 
eeAChE and equine BChE inhibition, respectively, in the same assay conditions), they were more potent 
Aβ42 aggregation inhibitors than the reference compound propidium iodide and the monomeric 2-amino-
4-phenylthiazole and 2-amino-4-[(4-methoxy)phenyl]thiazole (57%, 11%, and 12% inhibition at 20 μM, 
respectively). Interestingly, the Aβ42 anti-aggregating activity of compound 16 was confirmed by atomic 
force microscopy. 
The thiazole and other related heteroaromatic rings in the form of benzofused systems were also 
conjugated to tacrine by the group of He and Li in the search for multi-target anti-Alzheimer agents [85]. 
Compounds 17 and 18 turned out to be potent inhibitors of eeAChE (IC50 17 nM and 58 nM, respectively) 
and equine BChE (IC50 122 nM and 156 nM, respectively) and moderately potent inhibitors of Aβ42 self-
aggregation (52% and 63% inhibition at 20 μM, respectively, with a ratio [I]:[Aβ42] 2:5), they being 
more potent AChEIs than the parent tacrine (IC50 311 nM, in the same assay conditions) and with similar 
Aβ42 aggregation inhibitory activity than the reference compound curcumin (52% inhibition at 20 μM, 
IC50 18.7 μM). Molecular docking experiments suggested that the tacrine-based hybrid 17 can 
simultaneously bind to both CAS (through the tacrine moiety) and PAS (through the benzothiazole 
moiety) of AChE, but its potential effect on the aggregation of Aβ induced by AChE was not determined 
[85]. 
The group of Marco-Contelles also used the structure of tacrine for the design of novel multi-target 
hybrid compounds, but in contrast with most approaches where tacrine was conjugated to a second 
pharmacophoric moiety through different linkers, they merged the structure of tacrine with that of the 
calcium channel blocker dihydropyridine drug nimodipine, which resulted in the design of the so-called 
tacripyrines, which keep the pharmacological activities of the parent compounds, i.e. AChE inhibitory 
activity and calcium channel blocking activity, and show neuroprotective and antioxidant properties 
[86,87]. Recently, this group prepared the methoxytacripyrine (S)-19 (Fig. 5) and its enantiomer by 
chromatographic resolution of the racemic compound [88]. According to kinetic studies, both 
enantiomers are mixed-type inhibitors of AChE, as suggested also by molecular docking studies, which 
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predicted different energetically favorable binding modes for both enantiomers of 19 either at the CAS of 
AChE or at the PAS. The (S)-enantiomer turned out to be more potent inhibitor of eeAChE (KI 16 nM vs 
125 nM for the (R)-enantiomer) but both enantiomers were roughly equipotent for inhibiton of the AChE-
induced aggregation of Aβ40 (29% and 25% inhibition at 100 μM, for (S)-19 and (R)-19, respectively) 
and self-induced aggregation of Aβ42 (89% and 84% inhibition at 50 μM, and with a ratio [I]:[Aβ42] 1:1, 
for (S)-19 and (R)-19, respectively, IC50 33 and 30 μM, respectively). Worthy of note, the ability of these 
compounds to inhibit amyloid fibril formation was confirmed by transmission electron microscopy 
(TEM). Curiously, despite the very similar in vitro biological profile of (S)-19 and (R)-19, only the (S)-
enantiomer was found to be able to protect neuroblastoma SH-SY5Y cells against the cytotoxicity 
induced by a short Aβ fragment (Aβ25-35) [88]. 
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Fig. (5). Chemical structure of the tacrine-dihydropyridine hybrid (S)-19. 
 
Memoquin derivatives 
Other dual inhibitors of AChE and Aβ aggregation have been recently developed from scaffolds other 
than tacrine. Memoquin (20, Fig. 6) is a very promising multi-target anti-Alzheimer compound which was 
designed some years ago by the group of Bolognesi by inserting the antioxidant benzoquinone moiety of 
ubiquinone into a polyamine scaffold that displayed AChE inhibitory activity [89,90]. A comprehensive 
in vitro biological characterization has shown that memoquin is able to potently interact with a number of 
important targets for AD treatment, namely, AChE and oxidative processes, as the parent compounds 
from which it was designed, but also BACE-1, and Aβ aggregation. More interestingly, a proof-of-
concept in a mouse model of AD showed that memoquin can positively affect the mechanisms behind 
neurodegeneration, thereby leading to cognitive enhancement [89,90]. In the light of the great potential of 
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memoquin as a disease-modifying anti-Alzheimer drug candidate, further studies have been carried out by 
the same group around the structure of memoquin to shed more light on the structure-activity 
relationships of this structural family and, eventually, to perform a lead optimization process. Thus, 
because the PAS and CAS of AChE are rich in hydrophobic amino acid residues, the group of Bolognesi 
studied the effect of the insertion of a methyl substituent at position α of the terminal benzylamino groups 
of memoquin on its multi-target profile [91], mainly with the hope that the additional methyl groups 
would lead to more tight interactions at both the CAS and PAS of AChE, thereby increasing the 
inhibitory activities against the catalytic and the Aβ pro-aggregating action of AChE. Indeed, the (R,R)-
stereoisomer (21, Fig. 6) exhibited a 3-fold increased inhibitory activity toward both processes (Table 2), 
while retaining the inhibitory activity of memoquin against Aβ42 self-aggregation  and hBChE 
(memoquin: IC50 1440 nM; 21: 1480 nM) [91]. Worthy of note, the meso (R,S)-stereoisomer exhibited 
similar potencies than 21 against the different tested targets. 
As previously mentioned, the high hindrance of some dimeric or hybrid AChEIs enable a better fit into 
the large substrate binding site of BACE-1, and as a result, some of these compounds exhibit significant 
BACE-1 inhibitory activities. However, the high molecular weight of such compounds might compromise 
membrane penetration, including BBB penetration. Even if it was not the case for memoquin, for which 
oral bioavailability and brain penetration had been confirmed [92], a series of memoquin analogs with 
lower molecular weights, and potentially better pharmacokinetic profile, were designed from memoquin 
through a disjunctive approach, i.e. by simplification of the structure of memoquin essentially by 
removing one of its 2-methoxybenzylaminoalkylamino chains [93]. The most interesting monomeric 
derivative of memoquin, 22 (Fig. 6), seems to keep the multi-target profile of memoquin, albeit with 
lower potencies. Molecular docking studies predicted a dual site binding of 22 to AChE, like the parent 
memoquin, which was in agreement with the high potency for its hAChE inhibition (Table 2), although 6-
fold lower than that of the dimeric memoquin. Also, lower, but still significant, potencies for inhibition of 
AChE-induced and self-induced Aβ aggregation and for BACE-1 inhibition (memoquin: >80% inhibition 
at 3 μM; 22: 60% inhibition at 3 μM) were found for 22 relative to memoquin [93]. Worthy of note, 
compound 22, which was less toxic than memoquin to primary chicken telencephalon neurons at a 
concentration up to 50 μM, inhibited the secretion of Aβ38, Aβ40, and Aβ42 in these cells with IC50 
values of 19, 21, and 46 μM, respectively [93]. 
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Fig. (6). Chemical structures of memoquin and derivatives thereof. 
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 Table 2. In Vitro Dual Inhibitory Activities of Memoquin Derivatives Against AChE and A 
Aggregation 
Compound hAChE  
(IC50 nM) 
AChE-induced 
A40 aggregation 
(% inhibition at 100 μMa 
and/or IC50 μM) 
self-induced 
A42 aggregation 
(% inhibition at 10 μMb  
and/or IC50 μM) 
memoquin, 20 1.55 87 / IC50 28.3 μM 67 
21 0.50 IC50 9.34 μM 64 
22 9.73 69 / IC50 45 μM 27 
23 198  22 
24 102  50 
25 21800  27 
26 22000  19 
27 31400  41 
28 305  26 
29 100  45 
30 256 17  
31 3.32 41 14 
32 0.37 >90 / IC50 8.13 μM 55 / IC50 9.69 μM  
a [I]=100 μM, [A40]=230 μM, [AChE]=2.30 μM, A40:AChE ratio 100:1. b [I]=10 μM, [I]:[A42] ratio 
1:5. 
 
Notwithstanding the promising multi-target profile of memoquin, its activities against AChE (low 
nanomolar range) and Aβ (micromolar range) are not well balanced. In order to discover memoquin 
analogs with more balanced multi-target profile, and with the assumption that the planar 2,5-
diaminobenzoquinone moiety of memoquin might play a pivotal role in the modulation of protein-protein 
interactions, the terminal 2-methoxybenzyl groups of memoquin were replaced with structural moieties 
from compounds with known amyloid binding abitity, such as the vanillic ring (as in compounds 23 and 
24, Fig. 6), benzofuran moieties (as in compound 25), benzothiazole system (as in compound 26) or 2-
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phenylbenzothiazole fragment (as in compounds 27 and 28) [94]. These structural changes resulted in a 
very important drop of hAChE inhibitory activity from the nanomolar to the micromolar or 
submicromolar range and in a slightly decreased Aβ42 anti-aggregating activity (Table 2), thereby 
affording weaker but more balanced multi-target lead compounds [94]. Interestingly, compound 23 at 10 
μM elicited a protective effect against the neurotoxicity induced by Aβ42 in neuroblastoma SH-SY5Y 
cells similar to that of memoquin (approx. 80% inhibition of neurotoxicity). 
The 2-methoxybenzyl group of memoquin has also been replaced by a unit of the antioxidant lipoic acid, 
with the expectation of deriving compounds with multiple antioxidant mechanisms, of interest for the 
treatment of AD [95]. The memoquin-lipoic acid hybrid 29 (Fig. 6) at 10 μM significantly decreased the 
ROS production in bovine heart submitochondrial particles and in human glioma cell line T67, and 
retained the dual inhibitory effect of memoquin against hAChE and Aβ42 aggregation, albeit with lower 
potencies, thereby resulting again in a more balanced multi-target profile (Table 2) [95]. Further removal 
of the aminohexylaminobenzoquinone fragment of memoquin and direct linkage of lipoic acid to the 
remaining N-ethyl-N-(2-methoxybenzyl)-1,6-hexanediamine moiety led to compound 30 (Fig. 6), which 
significantly decreased ROS production in SH-SY5Y cells, from 82% of increased intracellular ROS 
induced by tert-butyl hydroperoxide to 70% at 10 μM or to 38% at 50 μM [96]. Compound 30 also 
potently inhibits hAChE (Table 2) but again with clearly lower potency than memoquin, and had a very 
weak inhibitory activity against the AChE-induced Aβ40 aggregation [96]. 
Based on previous studies by Tumiatti et al. on dimeric polyamine based AChEIs containing N-ethyl-N-
(2-methoxybenzyl)aminoalkyl moieties similar to those of memoquin, which suggested that increasing 
rigidity within the linker, as in compound 31 (Fig. 6), increased Aβ anti-aggregating activity relative to 
flexible oligomethylene-linked counterparts [97], and taking into account that aromatic systems may 
enable additional interactions with aromatic amino acid residues at mid-gorge of AChE as well as 
inhibition of Aβ self-aggregation, the dipiperidino moiety of 31 was replaced by still more constrained 
cyclic systems as the 1,4,5,8-naphthalenetetracarboxylic diimide moiety of the novel analog 32 (Fig. 6) 
[98]. Indeed, as suggested by kinetic and docking simulations, compound 32 was able to simultaneously 
interact with CAS, PAS and mid-gorge aromatic residues, this three-site binding mode accounting for its 
higher hAChE and AChE-induced Aβ40 aggregation inhibitory activities relative to the potent AChEI 31 
(Table 2). Also, the insertion of the aromatic system in the linker of 32, as expected, endowed the 
compound with a significant inhibitory activity toward Aβ42 self-aggregation, in contrast with 31, which 
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was essentially inactive for this activity [98]. Worthy of note, the Aβ anti-aggregating activity of 32 was 
in the same range than that of propidium and only slightly lower than that of Congo red [98]. 
 
Natural products and natural-based compounds 
A number of dual inhibitors of AChE and Aβ aggregation are natural products or natural-based 
compounds. The structure of the isoquinoline alkaloid berberine, 33 (Fig. 7), with known AChE 
inhibitory activity [99], has been linked to different (hetero)aromatic systems. Thus, the group of He and 
Li has synthesized series of berberine-based hybrids substituted at position 9 of the berberine scaffold 
with a linker that connects it to a phenylbenzoheterocyclic system, as in compounds 34 and 35 (Fig. 7) 
[85], to a triazole ring, as in compounds 36 and 37 [100], to a benzenediol ring, as in compounds 38 and 
39 [101], to a melatonin moiety, as in compound 40 [101], or to a ferulic acid unit, as in compound 41 
[101]. Most berberine-based hybrids were less potent eeAChEIs than berberine, with IC50 values in the 
micromolar or submicromolar range, with the exceptions of compounds 36-38 (Table 3). Precisely, a dual 
site binding to AChE has been predicted by molecular docking experiments for compound 38, which 
seems to position its berberine moiety at the PAS and the triazole ring at the CAS of AChE [100], which 
might account for its higher AChE inhibitory activity relative to berberine. Conversely, all of these 
hybrids turned out to be more potent inhibitors of Aβ42 self-aggregation than berberine and another 
reference compound such as curcumin (52% inhibition of Aβ42 aggregation at 20 μM, IC50 18.7 μM). 
Worthy of note, in the case of the berberine-based hybrids bearing a polyphenol moiety (38, 39, 41) or a 
melatonin unit (40), the antioxidant activity of these scaffolds was preserved in the hybrids, which 
exhibited oxygen radical absorbance capacity (ORAC) values ranging from 3.4 to 9.5 Trolox equivalents, 
clearly higher than that of the parent berberine (0.4 Trolox equivalents)  [101]. 
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Fig. (7). Chemical structures of berberine and derivatives thereof. 
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Table 3. In Vitro Dual Inhibitory Activities of Berberine Derivatives Against AChE and A 
Aggregation 
Compound eeAChE  
(IC50 nM) 
self-induced 
A42 aggregation 
(% inhibition at 20 μMa 
and/or IC50 μM) 
Berberine, 33 374 36  
34 774 IC50 4.69 μM 
35 2120 IC50 3.75 μM 
36 44 53 
37 201 78 
38 123 85 
39 460 92 
40 1110 83 
41 3210 76 
a [I]=20 μM, [I]:[A42] ratio 2:5. 
 
The scaffold of oxoisoaporphine, which is present in the hybrid 14 (Fig. 4), has been used by the same 
group in the synthesis of a series of oxoisoaporphine derivatives substituted at position 10 with different 
basic side chains [102]. Among these derivatives, compounds 42 and 43 (Fig. 8) emerged as potent 
inhibitors of eeAChE (IC50 720 nM and 210 nM, respectively) and AChE-induced aggregation of A40 
(42: 88% and 61% of inhibition at 100 μM and 10 μM, respectively; 43: 94% and 74% of inhibition at 
100 μM and 10 μM, respectively), and also moderately potent inhibitors of equine BChE (IC50 1.13 μM 
and 2.81 μM, respectively). These compounds were less potent cholinesterase inhibitors than the 
reference compound tacrine (IC50 eeAChE 130 nM, IC50 equine BChE 21 nM, in the same assay 
conditions) and more potent inhibitors of the AChE-induced aggregation of A40 than the PAS inhibitor 
propidium (85% and 40% inhibition at 100 μM and 10 μM, respectively), but less potent than Congo red 
(97% inhibition at 100 μM and 10 μM). As in the case of propidium, the potent inhibitory activity of 
these oxoisoaporphine derivatives seems to arise from interaction with the PAS of AChE, as suggested by 
kinetic studies. Despite the close structural similarity between compounds 42 and 43, the former was 
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predicted by the PAMPA-BBB assay to be able to cross the BBB, whereas surprisingly a low BBB 
permeation was predicted for its upper homolog 43 [102]. 
 
NO
HN
N
n
42, n=2
43, n=3
S
N
O
N
R
OHH
H 44, R=m-OMeBn
45, R=m-CF3Bn
46, R=(CH2)3phthalimido
N
chelerythrine, 47
O
O
O
O
Cl
O
HO
OH
HO
OH
O
HO
OH
OH
OH
HO
HO
48
O
HO
R
OH
O
R'
O
HO
HO OH
OH
49, R=3,5-dihydroxyphenyl, R'= 4-hydroxyphenyl
O
O
O
O
O
O
50
O
O
O
O
O
N
H
O
51  
 
Fig. (8). Chemical structures of other natural products and natural-based compounds with dual Aβ 
aggregation and AChE inhibitory activities. 
 
Following a high-throughput screening campaign of an in-house library of natural products that led to the 
discovery of a tetracyclic triperpene hit with AChE inhibitory activity [103], the group of Guillou 
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developed a novel class of analogs incorporating structural modifications to enable an additional 
interaction with the PAS of AChE, apart from interactions at the CAS, thereby potentially leading to 
increased AChE inhibitory activity and also to inhibitory activity against the AChE-induced aggregation 
of Aβ [104]. Indeed, molecular docking and molecular dynamics simulations suggested that one of the 
novel analogs, compound 44 (Fig. 8), was able to simultaneously reach the CAS and the PAS of AChE, 
establishing mainly hydrophobic interactions. This might account for the very potent inhibitory activity of 
44 and other analogs such as 45 and 46 against hAChE (IC50 3 nM, 3 nM, and 14 nM, respectively) and 
for their significant inhibitory activity against the AChE-induced aggregation of Aβ40 (69%, 56%, and 
42% inhibition at 100 μM, respectively) [104]. These compounds were clearly more potent hAChEIs than 
the reference compound tacrine and the initial tetracyclic triterpene hit (IC50 484 nM and 299 nM, 
respectively, in the same assay conditions) and only slightly less potent inhibitors of the AChE-induced 
Aβ40 aggregation that the prototypic inhibitor of AChE PAS and of the AChE-induced Aβ aggregation 
propidium (85% inhibition at 100 μM). 
Screening of a commercial library of natural and natural-based compounds for AChE and BChE 
inhibitory activities allowed the identification by the group of Vuorela of chelerythrine, 47 (Fig. 8), as a 
hit compound for hAChE and hBChE inhibition (IC50 1.54 μM and 10.3 μM, respectively) [105]. Kinetic 
and docking simulations suggested that chelerythrine might bind to the PAS of AChE. Further biological 
profiling of this compound, showed that chelerythrine exhibits an interesting multiple Aβ anti-
aggregating action, as it is able to inhibit the self-aggregation of Aβ40 (IC50 4.20 μM) and the AChE-
induced aggregation of Aβ40 (49% at 5 μM, 65% at 10 μM, and 88% at 100 μM), and very interestingly, 
it is also able to disaggregate preformed Aβ40 aggregates (IC50 13 μM). Thus, chelerythrine emerges as a 
very promising anti-Alzheimer lead with multiple well balanced activities (all of them in the low 
micromolar range) [105].  
Analogously, in a screening campaign for AChE and BChE inhibitors from natural products, the extract 
of the roots of Vitis amurensis was selected, and  two resveratrol oligomers, compounds 48 and 49 (Fig. 
8), were isolated from this active extract [106]. Biological characterization of these compounds confirmed 
their moderately potent inhibitory activity against hAChE (IC50 1.04 μM and 1.66 μM, respectively) and 
hBChE (IC50 4.41 μM and 1.75 μM, respectively), they being roughly equipotent to the anti-Alzheimer 
AChEI drug galantamine (IC50 AChE 0.93 μM; IC50 BChE 9.24 μM, in the same assay conditions). 
Interestingly, both 48 and 49 also inhibited the self-aggregation of Aβ42 (61% and 39% at 10 μM, 
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respectively, with a ratio [I]:[Aβ42] 1:2.5) [106]. Thus, as in the case of chelerythrine, the multiple 
activities of these compounds, all of them in the low micromolar range, are well balanced, which is an 
important feature in multi-target drugs. 
Also, following a high-throughput screening of a plant extract library for AChE inhibition, an ethyl 
acetate extract of the fruits of Styrax agrestis was found to be able to inhibit AChE [107]. Subsequent 
bioassay-guided fractionation of this extract led to the isolation of the new egonol-type 2-arylbenzofuran 
50 (Fig. 8), which can inhibit both hAChE (IC50 1.7 μM) and the AChE-induced aggregation of Aβ40 
(78% at 100 μM). To expand the structure-activity relationships in this structural family, new egonol 
derivatives were prepared by semisynthesis from egonol, among which compound 51 (Fig. 8) displayed 
the most interesting profile (IC50 hAChE 4.5 μM; 87% inhibition of AChE-induced aggregation of Aβ40 
at 100 μM). Interestingly, both egonol derivatives were more potent inhibitors of the AChE-induced 
aggregation of Aβ40 than propidium (54% inhibition at 100 μM, in the same assay conditions), and only 
slightly less potent hAChEIs than tacrine (IC50 1.03 μM, in the same assay conditions) [107]. Molecular 
docking and molecular dynamics simulations suggested a simultaneous interaction of this kind of 
derivatives with both the CAS and PAS of AChE, which might account for their significant dual 
inhibitory activities. 
 
2-Arylbenzofuran derivatives 
Other synthetic 2-arylbenzofurans have been also developed for dual inhibition of AChE and Aβ 
aggregation. The group of Rampa combined the 7-(N-methyl-N-benzylamino)heptyloxy moiety of some 
previously developed cholinesterase inhibitors [108] and the 4-(2-furyl)phenoxy fragment of SKF-64346, 
an inhibitor of Aβ fibril formation [109], in the search for novel dual inhibitors of cholinesterases and Aβ 
aggregation [110,111]. Among the resulting benzofuran-based hybrids, compounds 52-55 (Fig. 9) 
emerged as the most interesting derivatives. Compounds 52-54 display not very strong but well balanced 
inhibitory activities against hAChE and the self-induced aggregation of Aβ25-35, a short Aβ peptide that 
retains the aggregation and neurotoxicity properties, exhibiting IC50 values in the low micromolar range, 
whereas compound 55 is more potent against hAChE and less potent for the Aβ25-35 anti-aggregating 
effect (Table 4). Worthy of note, all of these compounds also display a similar micromolar or 
submicromolar activity against hBChE (IC50 0.28 μM, 38.1 μM, 1.82 μM, and 2.88 μM, respectively) 
[110,111]. Interestingly, compounds 53 and 55 significantly protected neuroblastoma SH-SY5Y cells 
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against the neurotoxicity induced by Aβ25-35 (58% and 48% inhibition at 30 μM), this activity likely 
resulting from the hydrophobic properties of these compounds together with their putative ability to block 
the interaction of the Aβ peptide with the lipid bilayer of neuronal membranes [110,111]. Thus, it has 
been hypothesized that the benzoyl group of hybrids 53 and 55 is essential for the interaction with 
hydrophobic residues of Aβ25-35, particularly Ile31, Ile32, and Met35, that seem to be responsible for the 
aggregation and neurotoxic properties [112]. Worthy of note, at 30 μM hybrids 53 and 55 were found to 
be able to reduce the binding of Aβ25-35 to the cell membrane surface of SH-SY5Y cells and to inhibit 
the ROS formation induced by Aβ25-35, which would seem to be the mechanisms behind the 
neuroprotective effect of these compounds. 
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Fig. (9). Chemical structures of synthetic 2-arylbenzofuran derivatives. 
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Table 4. In Vitro Dual Inhibitory Activities of Synthetic Benzofuran-based Hybrid Compounds 
Against AChE and A Aggregation 
Compound hAChE  
(IC50 μM) 
self-induced 
A25-35 aggregation 
(% inhibition at 10 μMa 
and/or IC50 μM) 
52 32.6 IC50 7.0 μM 
53 40.7 47 / IC50 12.5 μM 
54 10.5 IC50 13.0 μM 
55 0.24 35 
a [I]=10 μM, [I]:[A42] ratio 1:10. 
 
Pyrimidine and triazine derivatives 
The group of Rao has developed a series of pyrimidine derivatives substituted at positions 2 and 4 with 
groups of different steric and electronic properties as dual inhibitors of AChE and A aggregation 
[113,114]. Some representative examples of these 2,4-disubstituted pyrimidines are compounds 56-59 
(Fig. 10), which exhibit moderate to weak potencies against hAChE and AChE-induced aggregation of 
A40 (Table 5) that might arise from a dual site binding to AChE as suggested by docking simulations 
with 58 [114]. Also, compound 59 was found to be weakly active as inhibitor of A40 self-aggregation 
(28% inhibition at 100 μM), and, together with 58, also active against equine BChE (58: IC50 3.9 μM; 59: 
IC50 7.6 μM). 
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Fig. (10). Chemical structures of 2,4-disubstituted pyrimidine derivatives. 
 
Table 5. In Vitro Dual Inhibitory Activities of 2,4-Disubstituted Pyrimidine Derivatives Against 
AChE and A Aggregation 
Compound hAChE  
(IC50 μM) 
AChE-induced 
A40 aggregation 
(% inhibition at 100 μM) 
56 24.9 59 
57 12.6 56 
58 8.0 31 
59 10.0 32 
 
Other nitrogen containing heterocycles such as triazines have been also used as the core of dual inhibitors 
of AChE and A aggregation. The group of Carotti has synthesized series of benzo[e][1,2,4]triazin-
7(1H)-ones, such as 60 (Fig. 11), and [1,2,4]-triazino[5,6,1-jk]carbazol-6-ones, such as 61, whose 
quinone/quinonimine and extended planar azaheterocyclic systems were expected to enable - stacking, 
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hydrophobic, and electrostatic interactions with A, thereby leading to an interference with the 
aggregation process [115]. Indeed, both compounds exhibit a potent inhibitory activity against A40 self-
aggregation (IC50 1.4 μM in both cases). Compound 60 also displayed eeAChE and equine BChE 
inhibitory activities in the same range than its A40 anti-aggregating activity (IC50 1.5 μM and 1.9 μM, 
respectively), whereas in the case of 61 these additional activities were not so well balanced (55% 
inhibition of eeAChE at 10 μM and IC50 BChE 25 nM) [115]. Worthy of note, further studies on the A 
anti-aggregating profile of 60 confirmed its ability to inhibit also the self-aggregation of A42 and 
suggested the stabilization of random coil arranged unstructured peptide as the mechanism underlying its 
inhibitory activity [115].  
Incorporation into a sym-triazine core of acetylcholine substrate analogs and multiple hydrophobic phenyl 
rings, which might improve -sheet intercalation into amyloid aggregates, has been used by the group of 
Kerman as strategies to confer both cholinesterases and A inhibitory activities [116]. Indeed, triazine 
derivatives 62-64 (Fig. 11) were found to be able to inhibit hAChE (IC50 9.7 μM, 0.3 μM, and 2.8 μM, 
respectively) and A40 self-aggregation (66%, 51%, and 72% at 100 μM, with a ratio [I]:[A40] 1:1). 
Also, the most hindered compounds 63 and 64 turned out to be moderately potent inhibitors of hBChE 
(IC50 3.9 μM and 15.3 μM, respectively). TEM studies confirmed the A anti-aggregating activity of 
triazines 62-64, which seemed to lead to the formation of globular aggregates instead of fibrillar 
structures [116]. Moreover, compounds 63 and 64 were nontoxic to neuroblastoma SH-SY5Y cells at a 
concentration as high as 400 μM. 
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Fig. (11). Chemical structures of triazine derivatives. 
 
Donepezil-related compounds 
Donepezil, 3, is the sole marketed dual binding site AChEI, with a proven, albeit weak, inhibitory activity 
against the AChE-induced A aggregation [35,55]. Several series of dual inhibitors of AChE and A 
aggregation have been designed from the structure of donepezil. The group of Muñoz-Torrero developed 
some donepezil-huprine hybrids bearing a donepezil-like 5,6-dimethoxy-2-[(4-piperidinyl)methyl]indane 
moiety [117], in which the indanone of donepezil had been replaced by an indane system on the basis of 
previous studies on a family of donepezil-tacrine hybrids where this replacement resulted in increased 
inhibitory activity against the AChE-induced aggregation of A40 [118]. A better dual site binding to 
AChE of these compounds relative to donepezil, as suggested by molecular dynamics simulations and 
kinetic studies, accounted for their improved dual inhibitory potencies. The most interesting compound of 
the series was the hybrid (–)-(7S,11S)-65 (Fig. 12, Table 6), which additionally was found to be a 
moderately potent inhibitor of hBChE (IC50 349 nM) and BACE-1 (IC50 11.0 μM) [117]. Moreover, this 
compound was predicted to be able to cross BBB in a PAMPA-BBB assay, and more importantly, it was 
confirmed to penetrate into the brain of OF1 mice (unpublished results). Despite the multi-target profile 
of compound 65, a proof-of-concept study in a transgenic mouse model of AD was not completely 
satisfactory, as this compound was able to improve cognition, likely by a purely cholinergic effect, but 
 31
not amyloid pathology (unpublished results), which likely reflects the significant difference in its 
potencies against cholinesterases (nanomolar range) and A (micromolar range), thereby highlighting the 
importance for multi-target compounds of having well balanced activities against the different targets. 
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Fig. (12). Chemical structures of donepezil-related compounds. 
 
 
 
 
 
 
 
 
 32
Table 6. In Vitro Dual Inhibitory Activities of Donepezil-Related Compounds Against AChE and 
A Aggregation 
Compound hAChE  
(IC50 nM) 
AChE-induced 
A40 aggregation 
(% inhibition at 100 μMa 
and/or IC50 μM) 
self-induced 
A42 aggregation 
(% inhibition at 10 μMb  
and/or IC50 μM) 
Donepezil, 3 21.4 22 <5 
65 2.61 42 29 
AP2238, 66 44 35 <5 
67 56 43 26 
68 52 48 27 
69 25 34  
a [I]=100 μM, [A40]=230 μM, [AChE]=2.30 μM, [A40]:[AChE] ratio 100:1. b [I]=10 μM, [I]:[A42] 
ratio 1:5. 
 
The group of Rampa has developed a series of hybrid compounds that conjugate the (N-benzyl-N-
methylamino)benzyl moiety of AP2238, 66 (Fig. 12), the first dual binding site AChEI purposely 
designed to hit both AChE and AChE-induced A aggregation [119], and a tetralone moiety, structurally 
related to the indanone system of donepezil [120]. The most interesting hybrids, 67 and 68, which seemed 
to be also dual binding site AChEIs according to kinetic studies, exhibited slightly lower AChE inhibitory 
potencies but increased A anti-aggregating effects than the parent compounds (Table 6), as well as 
significant hBChE inhibitory activities (IC50 8.05 μM and 5.01 μM, respectively). The same group 
developed some hybrid compounds that merged the (N-benzyl-N-methylamino)benzyl moiety of AP2238 
with another moiety structurally related to the indanone system of donepezil, namely a 
dimethoxybenzophenone scaffold [121]. Because the initial lead compound of this series was devoid of 
inhibitory activity against the AChE-induced aggregation of A, further modifications were carried out to 
increase this activity, which consisted of introducing at the benzophenone moiety aminoalkyl chains that 
might mimic the role of the diethylmethylammonium alkyl chain of the prototypic inhibitor of AChE 
PAS and, hence, of AChE-induced A aggregation propidium [122]. Indeed, the most interesting 
compound of the series, 69 (Fig. 12), exhibited improved hAChE and AChE-induced A40 aggregation 
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inhibitory potencies than the initial lead, it being equipotent to donepezil for hAChE inhibition but clearly 
less potent than propidium for inhibition of AChE-induced A aggregation (Table 6) [122], as the other 
previously mentioned donepezil-related derivatives. 
The group of Malawska has used another system structurally related to the indanone ring of donepezil, 
namely an isoindoline-1,3-dione scaffold, as the core of a series of dual inhibitors of AChE and A 
aggregation [123]. The most interesting compounds, 70 and 71 (Fig. 12), exhibit a significant inhibitory 
activity against eeAChE (IC50 1.2 μM and 1.1 μM, respectively) and against the self-aggregation of a 
short A peptide (34% and 39% inhibition at 80 μM, respectively, with a ratio [I]:[A] 1:1.25) [123]. 
The structure of donepezil has also inspired the design by the group of Ozadali of a series of 
acylhydrazones which incorporated the dimethoxybenzene and benzylpiperidine moieties of donepezil or 
related systems [124]. Compounds 72 and 73 (Fig. 12), as representative examples of this series, are 
rather weak inhibitors of hAChE (IC50 63 μM and 53 μM, respectively) and equine BChE (IC50 55 μM 
and 67 μM, respectively) but exhibit balanced inhibitory activity toward self-induced aggregation of both 
A40 and A42 (70-80% inhibition at 100 μM) [124]. 
 
Benzamide derivatives 
The group of Yang and Yang has reported the synthesis of a series of benzamides linked to a quinoline 
and to an acetophenone moieties, rationally designed as dual binding site AChEIs [125]. Compound 74 
(Fig. 13) was indeed predicted by docking simulations to be able to simultaneously reach both CAS and 
PAS of AChE. This compound exhibit potent inhibitory activities against hAChE (Ki 6.50 nM) and 
hBChE (Ki 55 nM) but lower inhibitory activities toward A42 self-aggregation (IC50 79 μM) and BACE-
1 (IC50 85 μM) [125]. 
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Fig. (13). Chemical structure of the benzamide derivative 74. 
 
Carbamate derivatives 
Most research endeavors on the discovery of novel anti-cholinesterase agents pursue reversible inhibitors. 
The group of Rampa has been involved in the development of pseudoirreversible AChEIs with additional 
activity against A aggregation [126]. Structural modification of an initial lead, xanthostigmine [127], 
had led to the design of novel phenylcoumarin and flavone derivatives, such as 75 and 76, respectively 
(Fig. 14) [126]. Docking and molecular dynamics simulations suggested a dual site binding to AChE for 
these compounds, which accordingly exhibited potent inhibitory activity against hAChE (IC50 1.20 nM 
and 0.73 nM), although unexpectedly quite weak AChE-induced A40 aggregation inhibitory activity 
(13% and 18% inhibition at 100 μM, respectively). 
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Fig. (14). Chemical structures of carbamate derivatives 75 and 76. 
 
As shown in this section, very intensive research is being carried out by an increasing number of groups 
toward the development of structurally diverse multi-target anti-Alzheimer agents, and particularly of 
those having at least a dual inhibitory activity against AChE and A aggregation (either spontaneous or 
AChE-induced). Much attention is paid to obtaining very high potencies at any target, maybe 
underestimating the crucial issue of balancing the different potencies at the multiple targets, which will 
eventually determine the in vivo efficacy of multi-target drug candidates. Therefore, it would be worth 
devoting more efforts to properly balancing the dual AChE and A aggregation inhibitory profile of 
already existing leads, even at the expense of a little drop of potency. 
 
SIMPLIFIED IN VIVO ASSAYS FOR THE SCREENING OF A ANTI-AGGREGATING 
COMPOUNDS 
The discovery of A anti-aggregating hit and lead compounds as well as the lead optimization process for 
increasing potency and/or balancing A anti-aggregating activity need robust and reliable methods for the 
evaluation of this activity. The screening of A anti-aggregating compounds is mostly carried out in vitro 
 36
through specific amyloid-like dyes as thioflavin-T (Th-T)-based fluorometric assays that use expensive 
synthetic peptides [35,36,128] and that seem not too easy to be implemented, inasmuch as amyloid 
aggregation is very sensitive to experimental conditions (purity of peptides, nature of solvents, 
concentrations of buffer solutions, incubation times, mixing conditions, or even the nature of the vessel 
surface, etc.) [9,15]. Apart from the high cost and technical difficulties, the sensitiveness of aggregation 
to the assay preparation conditions may lead to significant differences between assays performed in 
different conditions or by different researchers. Another important issue that applies for in vitro assays 
performed with isolated protein targets, in general, is the fact that they are increasingly perceived as being 
too far from the (patho)physiological conditions where these targets are expected to be hit by the drug 
candidates under evaluation. In living organisms proteins are not isolated but they are prone to interact 
with other molecules, and, indeed, they take part in complex interaction networks that are not present in 
in vitro tests [39,129,130]. In particular, amyloid aggregation seems to be greatly influenced in 
physiological conditions by interactions with other molecules such as metal ions, chaperones or proteases. 
These interactions are stimulated under the molecular crowding caused by the high concentration of 
macromolecules inside cells that favor processes as aggregation that lead to an increased available 
volume [131,132]. Because these key aspects of the biological complexity of amyloid aggregation cannot 
be captured in in vitro assays there is an increasing demand of novel phenotypic assays, which 
recapitulate better the physiological scenario of the amyloid aggregation process and its inhibition, which 
are less expensive than classical in vivo studies with mouse models and in vitro tests with synthetic 
peptides, and which are simple, rapid, and reliable. 
In this light, bacteria are emerging as suitable models to monitor protein aggregation [132]. Protein 
aggregation occurs intracellularly in bacteria, at least during the overexpression of heterologous genes, 
usually in the frame of the production of recombinant proteins for biotechnological purposes. Indeed, the 
high translation rate in bacteria results in high intracellular concentrations of the recombinant proteins, 
and in these conditions, as mentioned above, aggregation is favored over other processes such as protein 
folding, thereby leading to the formation of insoluble protein deposits called inclusion bodies (IBs) [133-
135]. IBs are very dense particles that can be formed in the cytoplasmic or in the periplasmic space of 
bacteria, which were initially regarded as amorphous aggregates, devoid of any ordered structure and 
activity and thought to result from molecular mechanisms completely unrelated with those mediating 
protein deposition in eukaryotic cells. Consequently, not only IBs constituted a serious bottleneck for the 
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biotechnological production of proteins in bacteria, but also they were considered to be useless for basic 
or applied research purposes [136]. Contrary to the initial assumptions, it has been recently found that 
bacterial IBs share common features and common mechanisms of formation and even toxicity with highly 
ordered amyloid structures, including the ability to seed further amyloid formation [137-141]. Thus, X-
ray diffraction, Fourier transform infrared spectroscopy (FTIR), and circular dichroism experiments have 
demonstrated the presence of amyloid-like structures inside IBs with -sheet motifs, which render IBs 
amenable to tinction with specific amyloid-like dyes such as Th-T or Congo red [140].  
In the light of the similarities between bacterial IBs and amyloid aggregates and of the easy genetic and 
biochemical manipulation of bacteria, bacterial IBs are emerging as a very interesting tool for studying 
protein aggregation processes and for screening protein aggregation inhibitors, as well [135]. 
Thus, aggregation of a given protein or peptide of interest can be monitored inside bacteria, particularly in 
Escherichia coli, genetically engineered to express a fusion protein where a given protein or peptide is 
fused to a functional reporter protein that can elicit a readily measurable property that is blocked upon 
peptide-triggered aggregation of the entire fusion protein or enabled by peptide aggregation inhibitors that 
block or delay the aggregation of the peptide thereby allowing a correct folding of the reporter protein, 
which becomes functional. One of such reporter proteins, widely used in these studies, is the green 
fluorescent protein (GFP) [139,142,143].  
The group of Hecht and Chang have developed a method for the screening of A42 aggregation inhibitors 
that is based on the use of E. coli cells expressing an A42-GFP fusion protein [144]. Induction of the 
expression of such fusion protein within E. coli in the absence of A42 aggregation inhibitors leads to 
misfolding and aggregation of the A42 sequence, which in turn triggers the misfolding of the whole 
fusion protein, thereby preventing the folding of GPF into its correct fluorescent structure. Conversely, 
addition of inhibitors of A42 aggregation to 96-well plates containing the E. coli cells before the 
induction of the expression of the A42-GFP fusion protein will eventually result in a blockade of the 
aggregation of the A42 sequence, and hence of the fusion protein, thereby allowing a proper folding of 
the GFP moiety into its native fluorescent structure, giving rise to a measurable fluorescent emission 
signal. Indeed, by using this methodology several inhibitors of A42 aggregation have been identified 
from a library of about one thousand triazine derivatives in only several hours [144]. Interestingly, 
conventional in vitro assays using synthetic A42 confirmed the A42 anti-aggregating activity of one 
compound, selected among those identified in the in vivo test, thus highlighting the reliability of the in 
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vivo test for the identification of A42 anti-aggregating hit compounds, apart from its simplicity, cost-
effectiveness, reproducibility, and scalability through robotization technologies [144]. Moreover, this in 
vivo test selects compounds that are nontoxic and membrane permeable. Even if these properties are 
desirable for drugs, some initial hits, either toxic to E. coli cells or unable to cross their membranes but 
otherwise active as inhibitors of A42 aggregation, whose toxicity or membrane permeability profile 
might be subsequently optimized in a classical hit-to-lead process, will remain undetected, and therefore 
lost, in the in vivo screen [144]. 
These limitations can be overcome using in vitro tests that use purified IBs previously formed in E. coli, 
and consisting of an A42-GFP fusion protein, as reported by the group of Ventura [145]. This method 
involved the initial induction of expression of the fusion protein, followed by isolation and purification of 
the formed IBs by centrifugation and resuspension in lysis buffer. The obtained purified IBs were 
subjected then to an in vitro refolding assay which consisted of denaturation of the aggregates contained 
in the IBs and dissolution in refolding buffer [145]. By adding different compounds to the refolding 
buffer and measuring the resulting fluorescence signal, pro-aggregating and anti-aggregating compounds 
can be identified by monitoring the recovery of GFP fluorescence upon folding. Using this method, the 
group of Ventura confirmed the A42 pro-aggregating action of metal ions, namely Cu2+, Ni2+, and Zn2+, 
and identified several inhibitors of metal-promoted A42 aggregation [145]. Even if the screening of 
A42 aggregation inhibitors is carried out under in vitro conditions, it avoids the use of expensive 
synthetic peptides, is rapid, simple and amenable to high-throughput scale. 
An analogous in vivo approach to that developed by the group of Hecht and Chang, but conceptually 
more complex, has been reported by the group of DeLisa, using a tripartite fusion protein instead of 
A42-GFP [146]. The tripartite fusion protein was composed of: i) a signal peptide (ssTorA) that targets 
an export pathway to the bacterial periplasm, namely the twin-arginine translocation (Tat) system; ii) the 
enzyme -lactamase to confer ampicillin resistance to E. coli cells; and iii) A42. Upon aggregation of 
the A42 sequence of the tripartite fusion protein the folding quality control mechanism of Tat precludes 
the Tat-dependent export of the fusion protein to the periplasm, with which -lactamase can not localize 
there, thus resulting in low levels of bacterial resistance to ampicillin. Conversely, incubation of E. coli 
cells with inhibitors of A42 aggregation should allow the Tat-dependent export of the fusion protein to 
the periplasm, thereby resulting in an increased resistance to ampicillin. For a more easy detection of the 
periplasmic localization of -lactamase in living cells, a precursor of a fluorogenic substrate of -
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lactamase (CCF2/AM) was added to the cell cultures. Cleavage of the fluorogenic substrate of -
lactamase (CCF2), which resulted in a measurable strong blue fluorescence, needed a previous hydrolysis 
of the substrate precursor CCF2/AM by a periplasmic cutinase enzyme that had to be heterologously 
expressed by the E. coli cells. Thus, this complex engineered assay with E. coli involved the induction of 
the coexpression of cutinase and the ssTorA-A42--lactamase fusion protein, after having added to the 
culture medium the potential A42 anti-aggregating compounds, followed by addition of CCF2/AM and 
measurement of the fluorescence and cell density of each well. A large library of triazine derivatives was 
screened using this method, and the positive A42 aggregation inhibitor hits were confirmed by a 
conventional in vitro assay using synthetic A42 [146]. 
Alternatively to the use of protein reporters, A42 aggregation can be also monitored in vivo through the 
use of conformational-sensitive dyes [132]. The group of Sabate and Ventura has recently developed a 
new method for monitoring A42 aggregation within intact E. coli cells that takes advantage of the 
membrane penetration of the amyloid dye thioflavin-S (Th-S) and of the high-speed high-throughput 
amenable flow cytometry to detect Th-S fluorescence [147]. Sabate has also developed a simple 
quantitative method for the in vivo screening of A42 aggregation inhibitors based on the direct Th-S 
staining of IBs within living E. coli cells and determination of Th-S relative fluorescence. Using this 
method, the percentages of inhibition of A42 aggregation in vivo of several inhibitors were found to be 
very similar to those previously determined with a classical in vitro assay with synthetic peptide, albeit 
slightly lower, likely as a result of a noncomplete penetration of the compounds through the bacterial 
membrane as well as the different expression levels of the recombinant A42 (Pouplana, S. et al., 
submitted). Very interestingly, the possibility of applying this method in automated technologies, like 
UV/Vis plate reader assays, might allow a rapid, simple, quantitative, and unexpensive in vivo testing of 
large compound libraries. 
 
CONCLUSION 
Huge research efforts and financial investement are eagerly pursuing the development of drugs that may 
efficiently treat AD, the so-called disease-modifying drugs, as they represent an acute unmet medical 
need. It is increasingly accepted that drugs that can hit simultaneously multiple biological targets involved 
in the neuropathogenesis of AD, regarded as a pathological networtk of interrelated protein targets instead 
of as a single-protein induced straightforward process, are the most viable option to efficiently confront 
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the disease. Among multi-target anti-AD drug candidates, dual inhibitors of Aβ aggregation and AChE 
are especially sought. A large number of synthetic, natural or semisynthetic compounds are being 
prepared or isolated and profiled against these two targets, and in many cases also against other biological 
targets of interest such as BACE-1 or oxidative stress, and some candidates with properly balanced 
multiple potencies are being discovered. However, to expedite the discovery of such candidates some 
innovations both at the early and late phases of the drug discovery process are necessary.  
At the early phases of hit identification and hit-to-lead processes simple in vivo methods for the screening 
of Aβ aggregation inhibitors are being developed that avoid the use of expensive synthetic Aβ peptides, 
which become cost-prohibitive in high-throughput screening of large compound libraries, and the 
artificiality of conventional in vitro assays. In vivo screening methods using bacterial IBs are emerging, 
which rely on the detection of the function of a reporter protein fused to Aβ or on the direct detection of a 
fluorescent signal upon binding to Th-S dye within living E. coli cells. These in vivo methods allow a 
rapid, reliable, reproducible, and cost-effective screening of Aβ aggregation inhibitors and are amenable 
to high-throughput automated technologies. 
At the final stages of drug development, the clinical success of dual inhibitors of Aβ aggregation and 
AChE, as well as of any other putative disease-modifying anti-Alzheimer drug, greatly depends on the 
possibility of initiating treatment very early in the course of AD, before widespread neurodegeneration 
and severe brain damage has already occured. For this purpose, the discovery of sensitive and reliable 
biomarkers and imaging agents that can allow an early diagnosis of AD, at the presymptomatic phases, is 
essential, inasmuch as they would enable both initiation of an early treatment and assessment of the 
effectiveness of disease-modifying drug candidates. 
 
ABBREVIATIONS 
Aβ  = β-Amyloid peptide 
AChE   = Acetylcholinesterase 
AChEI  = AChE inhibitors 
AD  = Alzheimer’s disease 
APP  = Amyloid precursor protein 
BBB  = Blood-brain barrier 
BChE  = Butyrylcholinesterase 
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CAS   = Catalytic anionic site 
eeAChE  = Electric eel acetylcholinesterase 
GFP   = Green fluorescent protein 
hAChE  = Human acetylcholinesterase 
hBChE  = Human butyrylcholinesterase 
I  = Inhibitor 
IBs  = Inclusion bodies 
ORAC  = Oxygen radical absorbance capacity 
PAS  = Peripheral anionic site 
ROS  = Reactive oxygen species 
TcAChE = Torpedo californica acetylcholinesterase 
TEM  = Transmission electron microscopy 
Th-S  = Thioflavin-S 
Th-T  = Thioflavin-T 
Tat  = Twin-arginine translocation 
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